Linked Life Data

10150496

Source:http://linkedlifedata.com/resource/pubmed/id/10150496

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1995-8-18
pubmed:abstractText
Focus groups were conducted with physicians, pharmacists and patients prior to semi-structured interviews with physicians and patients. The survey was conducted in Spain, Germany and the UK. There were high levels of awareness of environmental issues, with ozone layer damage and global warming being of particular concern. Most respondents were aware of chlorofluorocarbon (CFC) use in aerosols and in refrigerators. However, their presence in asthma metered dose inhalers (MDIs) was much less widely known. German physicians had the highest awareness (78%) while only 1 in 10 of UK patients was aware. Patients expressed concern on learning that they inhale CFCs. Reaction to the concept of a non-CFC propellant was universally favourable, though sometimes qualified with the need for adequate safety and efficacy data. Patients expected to be informed of the change by doctors, pharmacists or patient information leaflets. Physicians expected to receive information as soon as possible but did not want patients informed until launch. Manufacturers and representatives would be the primary information sources for physicians. Pack changes should be minimised. Communicating the change to non-CFC propellants to physicians, pharmacists and patients is all important.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
T
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0894-2684
pubmed:author
pubmed:issnType
Print
pubmed:volume
8 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S49-52
pubmed:dateRevised
2000-12-18
pubmed:meshHeading
pubmed:year
1995
pubmed:articleTitle
Prescribers' and users' perspective of CFCs: a market research survey.
pubmed:affiliation
Glaxo Research and Development Ltd, Uxbridge, Middlesex, UK.
pubmed:publicationType
Journal Article